Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

Rhea-AI Summary

Exelixis (NASDAQ: EXEL) has announced its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference. The company's President and CEO, Michael M. Morrissey, Ph.D., will deliver a corporate overview presentation on Monday, January 13, 2025, at 5:15 p.m. PT / 8:15 p.m. PT.

The presentation will be accessible via webcast through the company's website at www.exelixis.com, specifically on the Event Calendar page under the Investors & News section. For those unable to attend live, replay access will remain available on the same platform for a minimum of 30 days following the presentation.

– Presentation to be webcast on www.exelixis.com –

ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the 43^rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 5:15 p.m. PT / 8:15 p.m. PT.

To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. Replays will also be available at the same location for at least 30 days.

About Exelixis

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX^® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com, follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.

Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250106026067/en/

Investors Contact:

Varant Shirvanian

Director, Investor Relations

Exelixis, Inc.

650-837-7917

vshirvanian@exelixis.com

Media Contact:

Hal Mackins

For Exelixis, Inc.

415-994-0040

hal@torchcommunications.com

Source: Exelixis, Inc.

FAQ

When is Exelixis (EXEL) presenting at the 2025 J.P. Morgan Healthcare Conference?

Exelixis will present at the conference on Monday, January 13, 2025, at 5:15 p.m. PT / 8:15 p.m. PT.

How can investors watch Exelixis's 2025 J.P. Morgan Healthcare Conference presentation?

Investors can watch the presentation via webcast by visiting www.exelixis.com and navigating to the Event Calendar page under the Investors & News section.

How long will the replay of Exelixis's J.P. Morgan Healthcare Conference presentation be available?

The presentation replay will be available on Exelixis's website for at least 30 days after the event.

Who will be presenting on behalf of Exelixis (EXEL) at the 2025 J.P. Morgan Healthcare Conference?

Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide the corporate overview presentation.